Overview

A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS)

Status:
Completed
Trial end date:
2019-09-10
Target enrollment:
Participant gender:
Summary
This study is to compare the systemic exposure of budesonide delivered by the combination inhaler (budesonide/albuterol sulfate pressurized inhalation suspension [BDA metered dose inhaler {BDA MDI}]) with Pulmicort Flexhaler dry-powder inhaler (DPI).
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide